Trial Profile
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Monascus (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Beijing Peking University WBL Biotech
- 01 Jun 2012 Planned End Date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov record.
- 01 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 29 Apr 2011 New trial record